pharma · Dermatitis, Atopic · Cancer
Janssen-Cilag Pty
Janssen-Cilag Pty Ltd
Janssen-Cilag S.p.A is a pharma organization headquartered in SYDNEY, IT. Primary therapeutic focus areas include Dermatitis, Atopic, Cancer, Ulcerative Colitis. NovaPharmaNews links 3 clinical program(s), 19 drug profil
SYDNEY, IT HQ
118 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- SYDNEY, IT
- Employees
- 118
- Programs
- 3
- Drugs
- 24
- Patents
- 0
CNTO148UCO3003
Phase 3 · small molecule · Ulcerative Colitis
CNTO148UCO3003 for Ulcerative Colitis is a Phase 3 program (small_molecule) at Janssen-Cilag Pty Ltd with 1 ClinicalTrials.gov record(s).
Internal code CNTO148UCO3003
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Janssen-Cilag Pty Ltd
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Ulcerative Colitis
- Status
- active
- Trials
- 1